MedTrace Logo

Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients

NCT04248348 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2020-01-30

No results posted yet for this study

Summary

During MeTHOS study will be collected Real World Data the clinical practice regarding Thromboprophylaxis in high thrombotic risk solid tumors patients undergoing surgical and /or chemotherapeutical treatment, for one year following the protocol initiation date.

Specifically focus will be on the following:

* Number of thrombotic events
* Anti-thrombotic management dosage \& duration
* Any bleedings related to anticoagulation
* Patients' adherence and compliance

Conditions

Interventions

DRUG

Low Molecular Weight Heparin

Cancer patients will be protected against thrombosis using Low Molecular Weight Heparin (LMWH)

Sponsors & Collaborators

  • Metaxa Hospital

    lead OTHER

Principal Investigators

  • Nikos Ziras, MD · Metaxa Hospital

  • Spyridon Xynogalos, MD · Metaxa Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04248348 on ClinicalTrials.gov